Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
AKTS compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name
AKTS
Aktis Oncology, Inc.
Change
Mkt cap
Revenue
Revenue
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
vs
Compare
AKTS
Aktis Oncology, Inc.
vs
LLY
ELI Lilly & Co
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
AKTS
Aktis Oncology, Inc.
Change
14.63
· pre 14.95
Mkt cap
$826.2M
Revenue
$3M
Q2 FY26
Revenue
—
LLY
ELI Lilly & Co
Change
1,407.25
· pre 1,448.38
Pre-market
Nov 4 '26
Mkt cap
$1.3T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
vs
Compare
Pre-market
Nov 4 '26
AKTS
Aktis Oncology, Inc.
vs
LLY
ELI Lilly & Co
14.63
pre 14.95
Price
1,407.25
pre 1,448.38
$826.2M
Mkt cap
$1.3T
Q2 FY26
$3M
Revenue
$24.4B
Q3 FY26
—
Revenue
$65.2B
FY25
Change
Change
AKTS
14.63
vs
LLY
1,407.25
Pre-market
Nov 4 '26
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
AKTS: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only AKTS
0
None
Shared
0
No disclosed counterparties: AKTS.
Only LLY
29
MCK
McKesson
customer
CAH
Cardinal Health
customer
VEEV
Veeva Systems
supplier
UTHR
United Therapeutics
customer
25 more · LLY chain
›
Role chip = supplier or customer
Source: SEC EDGAR
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
AKTS, solid
LLY, dashed